Eli Lilly & Co. v. Invagen Pharmaceuticals, Inc.
1:09-cv-00087; filed January 28, 2009 in the Southern District of Indiana
Infringement of U.S. Patent Nos. 6,458,811 (“Benzothiophenes Formulations Containing Same and Methods,” issued October 1, 2002), 6,797,719 (same title, issued September 28, 2004), and 6,894,064 (same title, issued May 17, 2005) following a Paragraph IV certification as part of Invagen’s filing of an ANDA to manufacture a generic version of Lilly’s Evista® (raloxifene, used for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk of invasive breast cancer). View the complaint here.
Courtesy of Patent Docs